UBS sees room for Daiichi Life to raise its Challenger bid
UBS analysts say Daiichi Life could extract enough synergies to lift its Challenger offer from A$11.80 to A$12.90–13.30 a share, per Market Talk.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Daiichi Life could gain enough synergies from Challenger, the Australian annuity provider, to justify a higher offer, according to analysts at UBS. After weighing capital and cost benefits, the bank's team thinks the Japanese insurer could raise its bid from A$11.80 a share to between A$12.90 and A$13.30.
Even without valuing Challenger's overseas growth plans, the analysts see A$12.40 to A$13.30 as a sensible band, they wrote in a note reported by Market Talk. The bank maintains a neutral view with A$12.25 as its target price. Shares traded at A$11.85 ahead of the open.
why it matters
The gap between the current share price and the suggested offer range shows how much of a bid increase investors may be weighing. For those following Australian insurers, the next step depends on whether Daiichi Life actually revises its proposal.
market impact
Challenger: a possible higher offer supports the insurer's share price
tags
instruments
sources
- Synergies May Justify an Improved Offer for Challenger — Market Talk, 26 October 2026 at 22:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗